Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population‐based cohort study

Abstract

Use of PDE5 inhibitors is associated with a small but significantly increased risk of sudden SNHL.

Predicting the Need for a Tier II Ototoxicity Study From Early Renal Function Data

“…According to the National Institute on Deafness and Other Communication Disorders 100 (https://www.nidcd.nih.gov/health/sudden-deafness), the drug-induced SSHL is characterized by a sudden or rapid loss of hearing and occurs in approximately 4,000 cases per year with an unknown etiology. 101 Liu et al 102 recently reported that the use of PDE-5 inhibitors is associated with a small but significantly increased risk of SSHL. Compared to nonuse, Liu et al 102 reported an adjusted hazard ratio of 1.25 (1.01-1.55) for current use with a risk difference of 1.97 (1.12-2.82) per 10,000 person-years.…”

“…101 Liu et al 102 recently reported that the use of PDE-5 inhibitors is associated with a small but significantly increased risk of SSHL. Compared to nonuse, Liu et al 102 reported an adjusted hazard ratio of 1.25 (1.01-1.55) for current use with a risk difference of 1.97 (1.12-2.82) per 10,000 person-years. For recent use, the adjusted hazard ratio was reported to be 1.60 (1.33-1.94) and risk difference was 3.19 (2.24-4.14).…”